Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Franck Emmanuel Nicolini, MD PhD, Delphine Rea, MD, Vincent Alcazer, MD, Francoise Huguet, MD, Laurence Legros, MD PhD, Gaelle Fossard, MD, Elodie Grockowiak, PhD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Mohamad Sobh, Mauricette Michallet, MD PhD, Francois Parant, PharmD, Marie-Claude Gagnieu, PharmD

Blood (2017) 130 (Supplement 1): 2901.

https://doi.org/10.1182/blood.V130.Suppl_1.2901.2901

Published: 2017

Journal Articles

Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis

Joseph G Schroers-Martin, MD, Florian Scherer, MD, Joanne Soo, BS, David M. Kurtz, MD, Chih Long Liu, PhD, Henning Stehr, PhD, Agnès Bru, Yasodha Natkunam, MD PhD, Maximilian Diehn, MD PhD, Bertrand Nadel, PhD, Sandrine Roulland, PhD, Ash A. Alizadeh, MDPhD

Blood (2017) 130 (Supplement 1): 308.

https://doi.org/10.1182/blood.V130.Suppl_1.308.308

Published: 2017

Journal Articles

Efficacy and Safety of Deferasirox in Chelation Naïve HbEβ Thalassemia Patients: Initial Experience from a Tertiary Centre of Eastern India

Debmalya Bhattacharyya, MDDM, Ranadip Chowdhury, MD, Soumita Choudhuri, Pramit Ghosh, MD, Maitreyee Bhattacharyya, DM

Blood (2017) 130 (Supplement 1): 4760.

https://doi.org/10.1182/blood.V130.Suppl_1.4760.4760

Published: 2017

Journal Articles

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Franck E. Nicolini, MD PhD, Gaelle Fossard, MD, Valerie Coiteux, MD, Viviane Dubruille, MD, Vincent Alcazer, MD, Mohamad Sobh, PharmD, Pierre Mouchel, MD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD, Agnes Guerci, MD PhD

Blood (2016) 128 (22): 1894.

https://doi.org/10.1182/blood.V128.22.1894.1894

Published: 2016

Journal Articles

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, MD, Jorge E. Cortes, MD, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera

Blood (2014) 124 (21): 3153.

https://doi.org/10.1182/blood.V124.21.3153.3153

Published: 2014

Journal Articles

Characteristics and Outcomes of Unselected Adolescents and Young Adults Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Stéphanie Bernardin, Franck E. Nicolini, MD PhD, Delphine Rea, MD PhD, Mael Haiblig, MD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, P Cony-Makhoul, MD, Martine Escoffre-Barbe, MD, Stephane Giraudier, Agnes Guerci-Bresler, MD PhD, Valérie Coiteux, MD, Marc G Berger, MD PhD Professor, Lydia Roy, MD, Anne Corby, MD, Pierre-Simon Rohrlich, MDPhD, Françoise Huguet, MD, Laurence Legros, MD PhD

Blood (2014) 124 (21): 1803.

https://doi.org/10.1182/blood.V124.21.1803.1803

Published: 2014

Journal Articles

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Blood (2014) 124 (21): 519.

https://doi.org/10.1182/blood.V124.21.519.519

Published: 2014

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

Guenter Auerswald, MD, Karin Kurnik, MD, Jan Blatny, MD, PhD, Armin J Reininger, MD

Blood (2013) 122 (21): 576.

https://doi.org/10.1182/blood.V122.21.576.576

Published: 2013

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

Stephen Opat, MBBS(Hons) FRACP FRCPA, Robert Bird, MD, Cecily J Forsyth, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Constantine S. Tam, MBBS, FRACP, FRCPA, Penelope Motum, MB BS PhD FRACP FRCPA, Mark A. Bentley, MBBS FRCPA FRACP

Blood (2011) 118 (21): 5050.

https://doi.org/10.1182/blood.V118.21.5050.5050

Published: 2011

Journal Articles

High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study

Daniela Cilloni, MD, PhD, Emanuela Messa, Lucia Biale, MD, Margherita Bonferroni, MD, Flavia Salvi, MD, Monia Lunghi, M.D., Bernardino Allione, Dario Ferrero, Roberto Freilone, MD, Alessandro Levis, MD, Giuseppe Saglio

Blood (2011) 118 (21): 611.

https://doi.org/10.1182/blood.V118.21.611.611

Published: 2011

Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators

Blood (2011) 118 (21): 1344.

https://doi.org/10.1182/blood.V118.21.1344.1344

Published: 2011

Journal Articles

Deferasirox Decreases Liver Iron Concentration (LIC) in Transfusional Iron Overloaded Patients with Myelodysplastic Syndromes (MDS), Aplastic Anemia (AA) and Other Rare Anemias: Results From 1-Year Multi-Center, Open-Label Phase II Study

Yutaka Kohgo, MD, PhD, Akio Urabe, MD, PhD, Yurdanur Kilinç, MD, Leyla Agaoglu, MD, Krzysztof Warzocha, MD, Guillermo Sanz, MD, Lay Cheng Lim, MD, Silvia Helou, MD, Dany Habr, MD, Isabelle Malet, PharmD, Sabine Glaser, Wieslaw Wiktor-Jedrzejczak, MD

Blood (2011) 118 (21): 4838.

https://doi.org/10.1182/blood.V118.21.4838.4838

Published: 2011

Journal Articles

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Vip Viprakasit, MD, DPhil, Norbert Gattermann, MD, Jong Wook Lee, MD, John B. Porter, MD, Ali Taher, MD, Dany Habr, MD, Bernard Roubert, PhD, Gabor Domokos, PhD, Maria Domenica Cappellini, MD

Blood (2010) 116 (21): 4272.

https://doi.org/10.1182/blood.V116.21.4272.4272

Published: 2010

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

Journal Articles

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter, on behalf of the EPIC study investigators

Blood (2010) 116 (14): 2448–2454.

https://doi.org/10.1182/blood-2010-01-261289

Published: 2010

Journal Articles

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

John B. Porter, Miranda Athanasiou-Metaxa, Donald K. Bowden, Jacques Troncy, Dany Habr, Gabor Domokos, Bernard Roubert, Diana Rofail, Adam Gater, Jean-François Baladi, M. Domenica Cappellini

Blood (2009) 114 (22): 2486.

https://doi.org/10.1182/blood.V114.22.2486.2486

Published: 2009

Journal Articles

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Ali Taher, Mohsen Saleh Elalfy, Amal El-Beshlawy, Dunhua Zhou, Lee Lee Chan, Chi-Kong Li, Kai-Hsin Lin, John B. Porter, Pranee Sutcharitcharan, Dany Habr, Gabor Domokos, Bernard Roubert, M. Domenica Cappellini

Blood (2009) 114 (22): 4058.

https://doi.org/10.1182/blood.V114.22.4058.4058

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2009) 114 (22): 4062.

https://doi.org/10.1182/blood.V114.22.4062.4062

Published: 2009

NARROW

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis

Efficacy and Safety of Deferasirox in Chelation Naïve HbEβ Thalassemia Patients: Initial Experience from a Tertiary Centre of Eastern India

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Characteristics and Outcomes of Unselected Adolescents and Young Adults Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Deferasirox Decreases Liver Iron Concentration (LIC) in Transfusional Iron Overloaded Patients with Myelodysplastic Syndromes (MDS), Aplastic Anemia (AA) and Other Rare Anemias: Results From 1-Year Multi-Center, Open-Label Phase II Study

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only